Chronic neuropathic pain remains inadequately treated, with current options limited by systemic side effects, short duration, or invasive procedures
Trames Bio is developing a new therapeutic paradigm: precise, circuit-level control of pain signaling, designed to deliver durable relief without the risks of opioids or irreversible interventions
ABOUT US
Redefining the Treatment of Chronic Pain
OUR FOCUS
High-Impact Indications in Neuropathic Pain
We are focused on severe neuropathic pain conditions with significant unmet need, high patient burden, and clear clinical endpoints
Alleviating the Significant Burden of Trigeminal Neuralgia (TGN)
A rare but severe facial pain disorder characterized by sudden, recurrent episodes of intense pain
-
400,000 patients across the U.S. and Europe
-
Limited efficacy of current pharmacologic treatments
-
Surgical interventions are invasive and often temporary or ineffective
Opportunity:
A targeted, durable therapy that eliminates the need for repeated procedures or systemic drugs
Trames Advantage
-
Local administration to trigeminal ganglion
-
Continuous nerve block without repeat procedures
Addressing the Chronic Epidemic of Lumbosacral Radiculopathy (LSR)
A common cause of chronic back and leg pain resulting from nerve root compression and inflammation
-
Millions of patients affected
-
Significant healthcare burden
-
Reliance on injections, opioids, or surgery
Opportunity:
A non-addictive, long-lasting treatment that addresses pain at its source
Trames Advantage
-
Intrathecal delivery enables broader coverage
-
Potential to reduce injections and surgeries
OUR PIPELINE
Revolutionizing the Treatment of Chronic Pain Disorders
Discovery
IND Enabling Pre-clinical
Clinical
Trigeminal Neuralgia
Lumbosacral Radiculopathy (Sciatica)
Undisclosed Pain Indications
Undisclosed Broader CNS Disorders
First in Human Trial Initiated in 2027
Platform improvements specific to pain neurons
Platform improvements addressing other sites of action
First In Human Readout in 2027
After injection of targeted AAV therapy, Trames technology seeks to deliver an on-demand nerve block regulated by an oral medication
Targeted Gene Delivery
A locally administered AAV vector delivers a gene encoding a proprietary inhibitory ion channel to specific pain neurons
Small Molecule Activation
An orally available small molecule selectively activates the engineered channel
Functional Outcome
Activation reduces neuronal excitability, suppressing pain signaling
Key Advantages
Precision
Expression is restricted to targeted neurons using cell-specific promoters
Control
Therapeutic effect is regulated by dosing of the oral small molecule
Reversibility
Neuronal activity returns to baseline when the activator is withdrawn
Durability
Gene expression enables long-term therapeutic potential from a single administration
OUR APPROACH
A New Modality for Neuromodulation
At Trames Bio, we are dedicated to improving the lives of people with chronic pain and other neurological diseases using chemogenetics to precisely target the neurons and neuronal circuits that cause disease
LEADERSHIP TEAM
To accomplish our mission, we’ve built a leadership team that is guided by decades of experience in neuroscience, gene therapy, and drug development and is driven to improve the lives of patients
CONTACT US
For general corporate or business development inquiries, please contact us. We would love to hear from you!